Olive Oil for High Risk Breast Cancer Prevention
https://www.facingourrisk.org/research-clinical-trials/study/97/olive-oil-for-high-risk-breast-cancer-prevention
Clinicaltrials.gov identifier:
NCT02068092 (https://clinicaltrials.gov/show/NCT02068092)
Study Contact Information:
For additional information, please contact: Houston Methodist Cancer Center by phone: 713-441-0629 or by email.
About the Study
This study will evaluate the effect of hydroxytyrosol, a component of olive oil, on breast density in women who are at high risk for developing breast cancer.
Hydroxytyrosol has been reported to impede the production and spread of various types of human cancer cells. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.
Type of Study
This is an open-label, single-group study. All study participants will receive the same treatment and screening.
What the Study Entails
- Participants will take 25mg hydroxytyrosol orally once daily for 1 year.
- Participants will have regular mammograms and breast MRI to assess breast density (as determined by mammography) and the safety/toxicity of hydroxytyrosol.
- Participants agree to undergo breast biopsy to measure biomarkers related to cancer risk.
- Participants will be followed for 3 years.
Study Sites
- Houston, Texas
Houston Methodist Hospital
Sub-Investigator: Jenny CN Chang, MD Sub-Investigator: Daniel Lehane, MD - Houston, Texas
Methodist Hospital Willowbrook
Principal Investigator: Anna Belcheva, MD - Sugarland, Texas
Houston Methodist Hospital Sugar Land
Principal Investigator: Jorge Darcourt, MD
Principal Investigator:
Tejal Patel, MD
This Study is Open To:
UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.
This Study is Not Open To:
UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.